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Abstract
We studied two monozygotic twins, born to first cousins, affected
by a multisystem disease. At birth, they both presented with bilat-
eral cryptorchidism and malformations. Since early adulthood, they
developed a slowly progressive neurological syndrome, with cere-
bellar and pyramidal signs, cognitive impairment, and depression.
Dilating cardiomyopathy is also present in both. By whole-exome
sequencing, we found a homozygous nucleotide change in XRCC4
(c.673C>T), predicted to introduce a premature stop codon
(p.R225*). XRCC4 transcript levels were profoundly reduced, and the
protein was undetectable in patients’ skin fibroblasts. XRCC4 plays
an important role in non-homologous end joining of DNA double-
strand breaks (DSB), a system that is involved in repairing DNA
damage from, for example, ionizing radiations. Gamma-irradiated
mutant cells demonstrated reduction, but not abolition, of DSB
repair. In contrast with embryonic lethality of the Xrcc4 KO mouse,
nonsense mutations in human XRCC4 have recently been associated
with primordial dwarfism and, in our cases, with adult-onset neuro-
logical impairment, suggesting an important role for DNA repair in
the brain. Surprisingly, neither immunodeficiency nor predisposi-
tion to malignancy was reported in these patients.
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Introduction
DNA breaks are severe injuries for cells, potentially leading to cell
cycle arrest and eventually death, accelerated aging, or oncogenic
transformation. During evolution, different DNA repair pathways
have evolved in order to minimize the deleterious impact of these
lesions, affecting either single or double-strand DNA (ssDNA,
dsDNA). These mechanisms include base excision repair (BER),
nucleotide excision repair (NER), and double-strand break repair
(DSBR) systems.
Two main DSBR pathways are known: homologous recombina-
tion (HR) (San Filippo et al, 2008) and non-homologous end joining
(NHEJ) (Lieber, 2010). While HR results in an error-free repair,
NHEJ is an intrinsically error-prone pathway. HR is a process
predominantly exploited by lower organisms, whereas both HR and
NHEJ concur to maintain chromosomal integrity in eukaryotes. In
mammals, particularly in human cells, the majority of DSBs are
repaired by NHEJ. The preferential involvement and efficiency of
NHEJ and HR repair systems vary during the different phases of the
cell cycle: NHEJ is active in all the cell cycle phases, whereas HR is
active only during the S and G2 phases. In fact, since HR relies on
the availability of undamaged templates to restore any lost sequence
information, it can operate only if a sister chromatid in close contact
to the damaged one is ready to be used as a template. Hence, in cell
cycle phases other than S/G2, since no sister chromatid is available,
NHEJ is the only option for cells to repair DSBs.
Non-homologous end joining is carried out by two main
complexes (Lieber, 2010): the DNA-dependent protein kinase (DNA-
PK) holoenzyme, formed by the KU70/KU80 heterodimer bound to
the DNA-PK catalytic subunit, and the DNA LIG4-XLF-XRCC4
complex; the former complex has a major regulatory role (Meek
et al, 2007), whereas the latter possesses the catalytic activity
responsible for DNA rejoining. DNA ligase IV (LIG4) is the NHEJ-
specific ligase; its stability is increased by interaction with the X-ray
repair cross complementing-4 (XRCC4) protein (Bryans et al, 1999).
A further component of the ligation complex is XLF/Cernunnos,
although it has been reported to be dispensable for DNA LIG4 stabil-
ity (Riballo et al, 2009). Very recently an additional protein, PAXX
(PAralog of XRCC4 and XLF, also called C9orf142), has been
described as a component of this machinery, with a role in binding
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KU70/KU80 and promoting DSBR through stabilization of NHEJ
protein assembly at DSB sites (Ochi et al, 2015). An alternative
NHEJ (A-NHEJ) process has been identified that does not require
the same proteins/enzymes used by Ku-dependent C-NHEJ (classic
non-homologous end joining) and that contributes to DNA rejoining
in the absence of DNA ligase IV (Wang et al, 2003; Goodarzi &
Jeggo, 2013).
The most severe DNA damage produced by ionizing radiation
(IR) consists in double-strand breaks.
Non-homologous end joining represents the major mechanism
for repairing two-ended DSBs such as those generated by IR, but
HR also plays a role, particularly in cycling cells during S/G2
phases.
Using whole-exome sequencing, we identified a XRCC4 nonsense
mutation, in two identical twin brothers born to consanguineous
parents.
Case reports
We studied two 50-year-old twin brothers (II-1 and II-2), born to
first-degree cousins. Their father, now in his seventies, is alive and
well; their mother committed suicide at 55 years. No information is
available on her psychiatric status before the event. A 47-year-old
sister (II-3) is alive and well (pedigree in Fig 1A).
II-1
Since birth, he presented with bilateral cryptorchidism, hypotelo-
rism, short limbs, pes cavus, and short stature. Alcohol addiction is
reported in young adulthood. At 27 years of age, he was diagnosed
a dilated cardiomyopathy, with hypertrophy of interventricular
septum and a residual ejection fraction of 25%; this condition was
attributed to his relevant alcohol intake, and treated with anti-
arrhythmic, anti-aggregant, and anti-hypertensive drugs. Since
44 years of age, he carries an ICD (implantable cardioverter defibril-
lator).
He reported gait difficulties and motor imbalance since 30 years
of age; at 46 years he experienced sudden worsening of gait
described as an “impaired control” of leg movements, which
became progressive over time.
At the time of our neurological assessment, subject II-1 (aged 48)
showed cognitive impairment (inability to count backwards),
nystagmus, and slowing of eye pursuits, dysarthria, dysmetria,
positive sensitized Romberg maneuver, and wide-based and
camptocormic gait with slight steppage and diffuse pyramidal signs,
requiring a cane for deambulation.
Routine blood laboratory tests did not show alterations besides
glucose intolerance (fasting blood glucose 120 mg/dl, normal values,
n.v. 50–110), moderately elevated total cholesterol (238 mg/dl, n.v.
110–200), a slight increase in alpha-fetoprotein (5.65 ng/ml, n.v.
0–5) in a smoking subject, and alteration of gonadotropins (FSH:
36.8 mU/ml, n.v. 1.4–18.1; LH: 22.3 mU/mL, n.v.1.7–8.6) with low
testosterone (1.13 ng/ml, n.v. 2.8–80) attributed to hypergonado-
tropic hypogonadism caused by bilateral cryptorchidism. Serum
lactate, pyruvate, and thyroid hormones were normal, as were
urinary organic acids. Immunologic evaluation showed only a slight
reduction in lymphocytes (1.21 × 103/ll, n.v. 1.50–3.50) and
neutrophils (2.31 × 103/ll, n.v. 2.50–7.50), with normal distribution
of immunoglobulins IgG, IgM, and IgA.
Neurophysiological studies revealed an axonal sensory neuro-
pathy, predominantly in the lower limbs. A brain MRI showed mild
atrophy of the cerebellar vermis. A muscle CT scan showed
increasing adipose muscle substitution. A muscle needle biopsy
was performed in the left quadriceps, and showed only type 2
fibers hypotrophy. Neurophthalmological assessment showed
normal fundi, but defective oculomotor control (nystagmus).
Cardiac assessment confirmed a dilating cardiomyopathy
(EF = 35%). Electroencephalography (EEG) showed slow basal
activity with slow left temporal theta–delta waves, but no epileptic
elements.
Neuropsychological assessment confirmed multiple-domain
impairment with relative sparing of language, consisting of severe
impairment of attention, visual perception, and verbal fluency by
phonetic or semantic stimuli, deficient short-term verbal and visuo-
spatial memory, and constructive apraxia.
II-2
II-2 showed cryptorchidism, low stature, hypotelorism, and short
limbs. From 48 years of age, he reported progressive gait impair-
ment, episodic neck and back pain, lower limb weakness, episodes
of dizziness, and depression. He did not report speech difficulties.
Multinodular thyroid hypertrophy was also present.
Neurological assessment reported horizontal nystagmus, impair-
ment of eye pursuits, pes cavus, dysarthria, dysmetria, diffuse
pyramidal signs, and ataxic and wide-based, mildly camptocormic
gait.
As also seen in his twin brother, routine blood tests did not show
alterations besides slightly elevated blood glucose (114 mg/dl) and
increase in total cholesterol (285 mg/dl). Blood levels of gonado-
tropines were elevated (FSH: 27.4 mU/ml; LH: 16.9 mU/ml), and
testosterone was low (0.84 ng/ml). Serum lactate, pyruvate, alpha-
fetoprotein, and thyroid hormones were normal. The profile of
urinary organic acids was normal as well. Immunologic evaluation
showed a slight reduction in total leukocytes (3.88 × 103/ll, n.v.
4.0–10.0), due to a decrease in neutrophils (1.69 × 103/ll, n.v.
2.50–7.50); IgG, IgM, and IgA levels were normal.
Neurophysiological studies revealed axonal sensory neuropathy,
with altered somatosensitive, motor, and brainstem auditory
evoked potentials. Visual evoked potentials and electroretinogram
were normal. Spinal and cerebral MRI was normal, with the
exception of mild atrophy of the cerebellar vermis. EEG did not
show epileptic elements. Cardiac assessment (ECG, echocardio-
gram and medical examination) revealed an initial left ventricular
diastolic defect (EF = 52%). A muscle needle biopsy was
performed in the left quadriceps, and showed only type 2 fibers
hypotrophy.
Neuropsychological assessment revealed severe attention deficit
with constructive apraxia, slow visual pursuit movements, difficul-
ties in lexical production after phonemic stimulation, and long- and
short-term visuo-spatial memory deficit.
Results
Informed consent for genetic and biochemical studies, in agreement
with the Declaration of Helsinki, was signed by the patients and
healthy family members participating in this study.
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Genetic studies
Karyotype and array CGH analyses did not detect any alteration;
mutations in TIM14 and FRDA were excluded by direct sequencing
in II-1. The analysis by both a forensic kit for genotyping and
homozygosity mapping unequivocally showed that the two affected
brothers are monozygotic twins.
We performed whole-exome sequencing on one proband (II-1)
and his unaffected sister (II-3). First, we filtered out common vari-
ants, with a frequency > 0.1% in public databases, including
dbSNPs, 1,000 Genomes, and Exome Variant Server. Then, based on
a hypothesized recessive trait and on the known parental consan-
guinity, we selected non-synonymous variants in coding regions and
splice-site junctions that were homozygous in II-1 and absent or
heterozygous in II-3. The remaining variants were prioritized accord-
ing to the predicted deleterious outcome of the corresponding amino
acid substitutions (Supplementary Table S1). The most severe
variant was the nucleotide change c.673C>T in XRCC4. Two different
isoforms of XRCC4, 334 and 336 amino acid (aa) long, respectively,
are produced by alternative splicing of the last exon, but the identi-
fied change is predicted to create in both a stop codon (p.R225*)
with loss of one-third of the protein at the C-terminus. This portion
of the protein contains a low-complexity domain with several sites
that can be phosphorylated by DNA-PK, causing loss of DNA end
bridging (Mahaney et al, 2013), whereas the head domain (aa
1–115) forming the hydrophobic core, and the stalk (aa 115–203), a
coiled-coil domain important for dimerization and interaction with
LIG4, are upstream the truncating mutation (Fig 1B). A form of
XRCC4 truncated for most of its C-terminus (aa 1–250) was reported
to be able to complement the radiosensitivity of XRCC4-deficient
cells (Koch et al, 2004). The variant was validated in affected
patients (II-1 and II-2) by Sanger’ sequencing and segregated within
the family, being heterozygous in both father (I-1) and healthy sister






Figure 1. Genetic and molecular features of XRCC4-mutant patients.
A Pedigree. Black symbols designate affected subjects.
B Schematic view of wild-type and mutant (R225*) XRCC4 proteins with their main domains and phosphorylation sites. The numbering refers to amino acids of refseq:
NP_071801.1. CTR: C-terminal region.
C Electropherograms of the XRCC4 genomic region encompassing the nucleotide substitutions in available members of the family.
D Quantitative real-time PCR of XRCC4 relative to GAPDH mRNA in affected (II-1 and II-2) and control (CT1 and CT2) fibroblasts. Each value refers to the mean of three
independent experiments performed in duplicate. Error bars indicate the standard deviation.
E Immunoblot analysis of total lysates from fibroblasts (fbs) and of in vitro-synthesized proteins (i.v.p). fl: in vitro-translated full-length XRCC4 protein; ret.: reticulocyte
lysate used for in vitro protein synthesis; 225*: in vitro-translated XRCC4 R225* truncated protein; Ct: lysate of control fbs; and II-1 and II-2: lysates of fbs from patient
II-1 and II-2. a-XRCC4 (Abcam, 1:1,000) and a-GAPDH antibodies were used.
F Immunoblot analysis of total lysates from fibroblasts using a-LIG4 (GeneTex, 1:1,000) and a-SDHA antibodies. Ct: lysate of control fbs; II-1 and II-2: lysates of fbs from
patient II-1 and II-2. The position of the molecular weight (MW) marker proteins is indicated.
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XRCC4 transcript and protein analysis
In order to evaluate the effect of the identified variant on the XRCC4
transcript, we performed quantitative PCR on cDNA obtained from
mRNA extracted from II-1, II-2, and control fibroblasts. We found
that XRCC4 transcript level was strongly reduced in mutant cells
(Fig 1D), probably due to nonsense-mediated mRNA decay.
Likewise, Western blot analysis showed undetectable XRCC4
protein in total lysates obtained from patients’ fibroblasts by
using two different polyclonal antibodies against XRCC4 (Fig 1E).
One antibody (Abcam) obtained using the full-length protein as
antigen clearly recognized an in vitro-translated construct corres-
ponding to the truncated XRCC4 protein; however, no signal was
detected in patients’ samples, demonstrating undetectable levels
of both wild-type (wt) and mutant protein (Fig 1D, Supplemen-
tary Fig S1). Immunofluorescence studies supported this result,
showing the absence of any nuclear signal in patients’ cells in
contrast to the labeling observed in control cells (Supplementary
Fig S2).
Notably, Western blot analysis revealed that, albeit reduced in
amount (40% of control mean), LIG4 was clearly present in lysates
from patients’ fibroblasts (Fig 1E).
Functional validation in mutant fibroblasts
To test the consequence of the XRCC4 mutation on DNA repair effi-
ciency, wt and mutant fibroblasts were first exposed to c-rays
(0.5 Gy), in order to induce DNA DSBs. After exposure to IR, the
extensive phosphorylation at Ser139 of histone H2AX results in the
formation of discrete c-H2AX foci, which can be identified by
immunostaining and constitute a useful tool to highlight the
presence of DSBs (Fernandez-Capetillo et al, 2004; Sharma et al,
2012). Because this phosphorylation is abundant, fast, and corre-
lates well with each DSB, it can be used to examine the DNA
damage produced by irradiation and the subsequent repair of the
DNA lesion (Svetlova et al, 2010). After irradiation, DSB rejoining
was monitored for 24 h, by measuring the formation of c-H2AX
nuclear foci, as a DNA damage index, and their disappearance, as
an index of DNA repair. During the 24-h monitoring, the decrease in
foci number was significantly slower in XRCC4-mutant fibroblasts
(XRCC4m/m #1, from individual II-1; XRCC4m/m #2, from individual
II-2) compared to that in wt cells, whereas at the endpoint, the
differences became statistically non-significant (Fig 2A). Since the
two XRCC4-mutant cell lines showed no significant differences in
DSB rejoining, these data were pooled and expressed as a mean in
subsequent analyses. The kinetics of c-H2AX foci disappearance
(Fig 2B) confirmed that in XRCC4-mutant cells, the DNA lesions
were repaired, although with lower efficiency than in wt cells, as
the percentage of foci remaining at 24 h was 5  8% in XRCC4wt
cells and 19  7% in XRCC4m/m. This result suggests that undetect-
able levels of XRCC4 protein do not completely abolish DNA repair
capability.
To analyze the contribution of the two main DSB repair
systems, NHEJ and HR, during cell cycle, we distinguished G1, S,
and G2/M cells on the basis of their nuclear immunofluorescence
intensity to the CENP-F protein, whose expression and localization
are cell cycle dependent. CENP-F is detectable by in situ immuno-
fluorescence throughout late S, G2, and M phases of the cell cycle,
but it is absent in G1 (Bee et al, 2013). By staining the cells with
a CENP-F antibody, we observed that in CENP-F-negative cells
(G1-phase), in which DSB rejoining is carried out by NHEJ,
DNA repair proceeded significantly slower in XRCC4m/m than in
XRCC4wt cells (Fig 3A), although at the 24-h endpoint, the differ-
ences became non-significant. In CENP-F-positive cells (late S and
G2 phase), in which HR system is fully active, DSBs repair was
similar at any time-point between wt and XRCC4-mutant cells
(Fig 3B).
Next, we compared the involvement of HR in repairing
DNA DSBs of XRCC4m/m and XRCC4wt fibroblasts, by analyzing
formation and disappearance during the G2 phase of nuclear foci of
RAD51, the central protein in the HR process (Fig 4). The number
of RAD51 foci at 2 and 6 h in XRCC4m/m cells was significantly
higher than in XRCC4wt cells. This result suggests ‘compensatory’
activation of HR in mutant NHEJ-defective compared to wt cells,
where, as normally observed in higher eukaryotes, NHEJ is the main
repair system active throughout the entire cell cycle. We could not
reliably measure the number of RAD51 foci at 24-h post-irradiation
endpoint because by then, only very few cells were in G2 phase
(Table 1) and the number of RAD51 foci/nucleus was negligible.
Our data show that in XRCC4m/m cells, the recruitment of HR factors
at DSB sites significantly increased compared to XRCC4wt cells,
partially supplying NHEJ impairment.
The fraction of cycling cells in a population of skin fibroblasts is
usually low. In our experimental conditions (Table 1), most of the
cells were in G1 phase, as detected by analyzing DNA content.
Before irradiation, 88.62  1.86% of XRCC4wt fibroblasts was in G1
phase and 6.41  0.35% in G2/M phases; 24 h after irradiation, G2
cells increased up to 11.09  0.80%, probably because of G2-check-
point activation. In XRCC4m/m non-irradiated cells, the percentages
of G1 phase was 92.23  0.43% and that of G2/M phases
5.25  1.47%. At 24 h after irradiation, XRCC4m/m cells in G1 phase
were 93.91  0.33% and those in G2/M were unchanged
(5.44  0.77%), probably because of failure of G2 checkpoint acti-
vation. Thus, the increased recruitment of HR factors to DNA
lesions detected in XRCC4m/m-mutant cells in G2 phase (RAD51 foci
in Fig 4), which was about 5% of the total, cannot explain the
persistence of the DNA repair level measured in our experiments.
We therefore analyzed the involvement of the alternative non-
homologous end-joining (A-NHEJ) pathway in DSB repair. The
nuclear enzyme PARP-1 is usually involved in SSB rejoining by BER
or NER processes, but in NHEJ-defective cells, it has been shown to
participate in DSB repair, as a component of A-NHEJ (Wang et al,
2006; Mansour et al, 2010; Mladenov & Iliakis, 2011). To calculate
the residual DSB rejoining upon inhibition of the A-NHEJ system,
we treated XRCC4wt and XRCC4m/m fibroblasts with a PARP-1
inhibitor, 30-aminobenzamide (30-AB), 24 h before irradiation
(Fig 5). From 2 h after irradiation, the number of c-H2AX foci in
30-AB treated XRCC4m/m cells was significantly higher than in
untreated XRCC4m/m cells. Conversely, in XRCC4wt cells, where DSB
repair is performed by the classical NHEJ (C-NHEJ) pathway, 30-AB
treatment did not modify the number of c-H2AX foci found in
untreated cells. We observed no difference in the amount of PARP-1
by Western blot analysis of XRCC4m/m vs. XRCC4wt cells, possibly
because of qualitative changes in distribution (e.g. relocation of the
protein within cell compartments) rather than quantitative
variations in content.
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From the number of c-H2AX foci in presence or absence of
PARP-1 inhibitor (Fig 6), we can roughly estimate the percentage of
DSBs induced by c-ray irradiation that were rejoined by the
A-NHEJ.
Albeit indirectly, our data suggested that the involvement of
A-NHEJ factors in repairing DSBs was irrelevant in XRCC4wt cells
(5  3% of DSBs repaired within 24 h), while it was clearly signifi-
cant in XRCC4m/m cells (19  4%).
Discussion
The homozygous non-sense mutation in X-ray cross complementing
gene 4 (XRCC4) found in our patients is predicted to result in the
premature truncation of the XRCC4 protein, which was in fact unde-
tectable in cultured mutant fibroblasts from both subjects. XRCC4
forms a complex with XRCC4-like factors, XLF/Cernunnos and
PAXX, and DNA ligase IV (LIG4) (Critchlow et al, 1997; Grawunder
et al, 1998a,b; Ahnesorg et al, 2006; Buck et al, 2006; Ochi et al,
2015), which operates the ligation step of NHEJ. Experimental
evidence indicated that perturbations of the XRCC4–XLF interaction
result in DSB repair deficits, including reduced frequency of coding
end joining during V(D)J recombination. These observations
suggested that, besides their well-characterized role in ligation step,
XRCC4 and XLF may have multiple functions during NHEJ, includ-
ing during early phases of the process, which may be independent
from LIG4 (Roy et al, 2012). The newly discovered component
PAXX functions with XRCC4 and XLF to mediate DSBR in response
to DSB-inducing agents, promoting assembly and/or stability of the
NHEJ machinery at DSB sites (Ochi et al, 2015). NHEJ is central to
DNA DSB repair mechanisms but also to the mechanism operating




Figure 2. Analysis of c-H2AX nuclear foci.
A c-H2AX nuclear foci in XRCC4wt and mutant fibroblasts (XRCC4m/m1 and XRCC4m/m2) were determined at different times after irradiation with 0.5 Gy of c-rays. Values,
subtracted of their non-irradiated control (1.3 foci/nucleus in XRCC4wt cells and 1.4 and 0.9 foci/nucleus in XRCC4m/m1 and XRCC4m/m2 cells, respectively), are the
mean  SD of three independent experiments.
B Percentages of c-H2AX foci in XRCC4wt and XRCC4m/m fibroblasts (pooled values) remaining at the indicated time-points.
C Immunofluorescence micrographs of c-H2AX foci in XRCC4wt and XRCC4m/m fibroblasts.
Data information: ***P < 0.001; **P < 0.01; *P < 0.05 (XRCC4m/m vs. XRCC4wt cells), two-way ANOVA, Bonferroni post hoc test.
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the hyper-variable regions in antibodies and T-cell receptors
(Helmink & Sleckman, 2012; Malu et al, 2012). Consequently,
disruption of NHEJ proteins (Ku, DNA-PKcs, XLF, LIG4, and
Artemis) often results in defects in DSB repair, radiation sensitivity,
and severe combined immunodeficiency (SCID) (Li et al, 1995;
Gu et al, 1997; Moshous et al, 2003; Buck et al, 2006). For instance,
the LIG4 syndrome (OMIM #606593), caused by mutations in LIG4,
is characterized by immunodeficiency, development and growth
delay, unusual facial features, and microcephaly. Accordingly, cells
from human patients with hypomorphic mutations in LIG4 are
radiosensitive, show impaired DSB repair, and display significantly
elevated chromosomal breaks upon IR exposures (Riballo et al,
2001). Likewise, the NHEJ1 syndrome (OMIM #611291), caused by
mutation in XLF, consists of severe combined immunodeficiency
(SCID), microcephaly, growth retardation, and sensitivity to IR.
However, neither immunologic abnormalities nor susceptibility
to cancer were part of the clinical phenotype of our XRCC4-mutant
patients. Similar observations have been performed in cells derived
from a patient with hypomorphic mutations in LIG4 that led to
pronounced radiosensitivity but did not cause any major immune
dysfunction, indicating that defects of DSBs repair are not necessar-
ily associated with immune dysfunction. (Riballo et al, 1999). A
homozygous missense variant in XRCC4 was recently identified in a
Saudi patient with primordial dwarfism, but it was not possible to
establish its causative role because of the absence of any experimen-
tal validation (Shaheen et al, 2014). While this paper was under
reviewing, two publications have reported patients with proven
mutations in XRCC4, associated with primordial dwarfism (Murray
et al, 2015) or early-onset metabolic syndrome (de Bruin et al,




Figure 3. c-H2AX nuclear foci formation in different cell cycle phases.
A, B Percentages of c-H2AX nuclear foci remaining in CENP-F-negative (A) and CENP-F-positive (B) cells at the indicated time-points after irradiation with 0.5 Gy of
c-rays. Values, subtracted of their non-irradiated controls, are the mean  SD of three independent experiments. ***P < 0.001; *P < 0.05 (XRCC4m/m versus
XRCC4wt cells), two-way ANOVA, Bonferroni post hoc test.
C Immunofluorescence micrographs of c-H2AX foci in CENP-F-positive and negative fibroblasts at 2 h after irradiation. Arrow heads indicate the CENP-F-positive
cells.
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and short stature, our patients were not diagnosed as having
primordial dwarfism and the main clinical feature was an adult-
onset progressive encephalocardiomyopathy. They presented also
cryptorchidism, suggestive of gonadal failure, which has been found
in other XRCC4-mutant patients (de Bruin et al, 2015; Murray et al,
2015). In only one patient (P2 in de Bruin et al, 2015), a malignant
tumor was reported, indicating that XRCC4 impairment is not
strongly associated with predisposition to malignancy. Taken
together, these reports, including our own, are concordant in
showing that, quite unexpectedly, mutations in XRCC4, a crucial
component of the NHEJ machinery, are not associated with immu-
nodeficiency in humans.
In mice, genetic knockout (KO) of XRCC4, as well as LIG4, leads
to embryonic lethality in conjunction with massive apoptotic death
of neuronal cells in the nervous system (Frank et al, 1998; Gao
et al, 1998; Chistiakov et al, 2009). Based on this observation in
mice, human XRCC4 mutations associated with primordial dwarfism
have been deemed as hypomorphic alleles (Murray et al, 2015).
However, most of the identified XRCC4 mutations are nonsense or
frameshift changes, predicting the synthesis of truncated proteins.
A
B
Figure 4. Involvement of homologous recombinations in repairing DNA DSBs.
A RAD51 foci in XRCC4wt and XRCC4m/m fibroblasts irradiated with 0.5 Gy of c-rays. Values are the mean  SD of three independent experiments. ***P < 0.001;
**P < 0.01 (XRCC4m/m versus XRCC4wt cells), two-way ANOVA, Bonferroni post hoc test.
B Immunofluorescence micrographs of RAD51 foci in XRCC4wt and XRCC4m/m fibroblasts. Arrowheads indicate the CENP-F-positive cells.
Table 1. Cell cycle distribution (percentage  SD).
IR
XRCC4wt XRCC4m/m
G1 S G2/M G1 S G2/M
 88.62  1.86% 4.97  0.58% 6.42  0.35% 92.23  0.05% 2.52  0.43% 5.25  1.47%
+a 84.54  2.90% 4.47  0.67% 11.09  0.80% 93.91  0.33% 0.65  0.21% 5.44**  0.77%
aCell cycle analysis has been performed 24 h after irradiation (IR).
**P < 0.01 G2/M percentage in mutant fibroblasts versus G2/M percentage in wt fibroblasts, two-way ANOVA, Bonferroni post hoc test.
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Although the persistence of small amounts of mutant protein retain-
ing some residual activity cannot be excluded, neither we nor others
were able to detect any trace of truncated XRCC4 species, at least in
patients’ fibroblasts. This does not exclude the possibility that, in
other cell types, mRNA decay or stability of the truncated protein
may be different and these cells may utilize the truncated protein
more effectively.
In contrast with previous reports suggesting that LIG4 is unstable
in the absence of its partner protein XRCC4 (Ghezraoui et al, 2014)
and is strongly reduced in XRCC4-mutant patients (Murray et al,
2015), we showed that LIG4 is moderately reduced in fibroblasts
from our patients; this evidence could explain their milder pheno-
type.
In our patients, undetectable levels of XRCC4 caused neither
immunologic defects nor increased susceptibility to cancer, and were
instead associated with a relatively mild syndrome, including moder-
ately severe congenital malformations, and a slowly progressive,
adult-onset combination of cardiac failure, due to dilating cardio-
myopathy, and neurological impairment characterized by cerebellar
failure, cognitive arrest/decline, and behavioral abnormalities. Both
patients are now 50 years old, and, albeit under constant tutoring,
they still carry on a largely autonomous daily lifestyle.
Interestingly, neurodegeneration with ataxic features has been
associated with defects in factors involved in signaling of DNA DSB
damage, for instance ataxia-teleangiectasia (A-T) syndrome (OMIM
#208900), a complex condition characterized by ataxia, teleangiecta-
siae, immunologic deficit, and predisposition to malignancy, caused
by ATM mutations; or ataxia-telangiectasia-like syndrome (OMIM
#604391), a phenocopy of, but milder than, A-T syndrome, caused
by MRE11A mutations. Mutations in APTX, encoding aprataxin,
cause autosomal recessive ataxia-oculomotor apraxia syndrome
(OMIM #208920). Aprataxin seems to play an ill-defined role in
regulation of NHEJ and detection of ssDNA breaks, by interacting
with XRCC1, XRCC4 (Clements et al, 2004; Ahel et al, 2006), or
PARP1 (Harris et al, 2009). In addition, defects in the repair of
ssDNA breaks also cause neurodegenerative diseases such as spino-
cerebellar ataxia with axonal neuropathy 1, SCAN1 (OMIM
#607251), caused by mutations in tyrosyl-DNA phosphodiesterase 1
(TDP1), and microcephaly, seizures and developmental delay,
MCSZ syndrome (OMIM #613402), caused by mutations in poly-
nucleotide kinase phosphatase (PNKP). Notably, both SCAN1 and
MCSZ show neither immunodeficiency nor cancer susceptibility.
Thus, preferential involvement of the brain, particularly the
cerebellum, is an intriguing feature of many disorders caused by
defects of DNA repair pathways, including the very one presented
here. Since HR is active only in proliferating cells, it is reasonable to
hypothesize that a defect in the constitutively active NHEJ pathway
Figure 5. Analysis of PARP-1 inhibition on DSB repair.
XRCC4wt and XRCC4m/m cells irradiated with 0.5 Gy of c-rays were exposed to the
PARP1 inhibitor 30-AB or to solvent (DMSO). The c-H2AX foci number is the
mean  SD of three independent experiments. *P < 0.05 (XRCC4m/m + 30-AB
versus XRCC4m/m + DMSO), ***P < 0.001 (XRCC4m/m + 30-AB versus
XRCC4wt + 30-AB), two-way ANOVA, Bonferroni post hoc test.
A B
Figure 6. Quantification of alternative non-homologous end-joining (A-NHEJ) activity.
A, B Percentages of DSBs repaired in increasing time intervals (0.5–2 h, 0.5–6 h, 0.5–24 h) were calculated in XRCC4wt (A) and XRCC4m/m (B) cells from the number of
c-H2AX foci in presence or absence of a PARP-1 inhibitor, 30-AB. **P < 0.01 (XRCC4m/m + 30-AB versus XRCC4m/m + DMSO), two-way ANOVA, Bonferroni post hoc test.
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can preferentially reduce the efficiency of DNA DBS repair in non-
proliferating, post-mitotic, highly specialized cells, such as neurons
(and cardiomyocytes). This consideration, together with evidence
that NHEJ efficiency declines with aging (Vyjayanti & Rao, 2006;
Vaidya et al, 2014), may explain the predominantly neurological
manifestations of defective DNA repair disorders, including those
associated with abolition of XCCR4.
Our study on patient-derived XRCC4m/m fibroblasts demonstrated
that the efficiency of IR-induced DNA DSBs repair was significantly
reduced, but not abolished, during a 24-h long monitoring, and at the
24th-h endpoint, it was very similar to that of XRCC4wt cells. As
increased HR activity of XRCC4m/m fibroblasts during the cell cycle
G2 phase involved a very small fraction of cell population, we
hypothesized the activation of other compensatory mechanisms. An
alternative end-joining pathway is reported to become active when
classical NHEJ is chemically or genetically compromised, operating
as backup, hence called “backup non-homologous end joining”
(B-NHEJ) or “alternative NHEJ” (A-NHEJ) (Wang et al, 2006; Iliakis,
2009). In in vitro studies, genetic defects of the NHEJ core component
are associated with increased radiosensitivity and decreased repair
efficiency of IR-induced DSBs. Defects in DNA-PKcs, as observed in
the tumor cell line M059J, which lacks the catalytic subunit of DNA-
PK, impair the efficiency of DNA repair, particularly for a decrease in
DSB rejoined by fast kinetics. However, in these cells the level of
residual DNA damage measured after long repair times is reduced
(by 50% or less) compared with that measured in DNA-PKcs-
proficient M059K cells (DiBiase et al, 2000; Bee et al, 2013). Similar
results were obtained using mutant cells deficient in Ku, LIG4, or
other components of classical NHEJ (Kabotyanski et al, 1998). These
results suggested that cells with compromised C-NHEJ are capable of
rejoining DNA DSBs, albeit through a repair pathway operating with
slow kinetics, by some vicarious DSB rejoining process. Several labo-
ratories have identified factors participating in the alternative path-
way of NHEJ: for instance, LIG3 (DNA ligase III; Simsek & Jasin,
2011), heretofore known only for its role in BER, was considered the
candidate ligase required for A-NHEJ (Wang et al, 2005); PARP1
(poly ADP-ribose polymerase 1) and XRCC1 (X-ray cross comple-
menting gene 1), two proteins known to interact with LIG3 during
BER, were subsequently found to be involved in A-NHEJ (Audebert
et al, 2004; Wang et al, 2006; Cheng et al, 2011). PARP1 is presumed
to compete with Ku for binding to broken DNA ends, thereby dictat-
ing the pathway of choice (Wang et al, 2006; Cheng et al, 2011),
whereas XRCC1 appears to act as a chaperone for LIG3 (Caldecott
et al, 1994). The A-NHEJ is thought to operate with much lower
fidelity than C-NHEJ and has been implicated in oncogenic genome
rearrangements, mainly chromosomal translocations, both in cancer
and in cultured cells (Be´termier et al, 2014). In our experiments, we
demonstrated that the A-NHEJ is active only in XRCC4m/m cells,
whereas it did not contribute to the DNA end rejoining in XRCC4wt
cells. However, in mutant fibroblasts treated with the A-NHEJ inhibi-
tor, 30-AB, DNA repair capability was significantly decreased but not
abolished, showing that, at least in those experimental conditions,
XRCC4m/m cells still retain the capability of rejoining more than 50%
of DSBs induced by irradiation. Taken together, our findings suggest
that some vicarious mechanisms, only partly relying on the activa-
tion of the A-NHEJ pathway, make the XRCC4 protein remarkably
dispensable in humans, at least to warrant immunologic proficiency
and anti-cancer surveillance.
Materials and Methods
Informed consent for participation in this study was obtained from
all investigated subjects, in agreement with the Declaration of
Helsinki and approved by the Ethical Committee of the Foundation
IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) Institute
of Neurology “Carlo Besta”.
Molecular studies
Total genomic DNA was extracted by standard methods from
peripheral blood lymphocytes. Total RNA was isolated from cell
pellets using the RNeasy Mini Kit (Qiagen) and reverse-transcribed
to GoTaq 2-Step RT-qPCR System (Promega), following manufac-
turer recommendations. XRCC4 expression in cDNA samples
obtained from DNase-treated mRNA was determined using reverse
transcription quantitative PCR (qPCR) with SYBR Green chemistry
and the following specific XRCC4 primers:
207F: TGGACTGGGACAGTTTCTGA, 270R: TCAGTTCACCAACATA
TTTCCC;
387F: GATGTCTCATTCAGACTTGGTTCCT, 458R: AAGTTCTCTAAT
GACTTCAGCTGGG.
GAPDH level was used for normalization.
Whole-exome sequencing
Whole-exome sequencing was performed on genomic DNA from II-1
and II-3 by “BGI-Shenzhen”. The DNA sample was randomly
processed in fragments between 200 and 300 bp. In-solution
targeted enrichment of exonic sequences was performed using the
64 Mb Exon Capture kit from Nimblgen. Then, the captured library
was sequenced on Hiseq2000 platform (Illumina). GeneTalk
(www.gene-talk.de) and Ingenuity Variant Analysis (www.ingenu-
ity.com) web applications were used for variant filtering. Poly-
phen2, SIFT, and Mutation taster were used for pathogenicity
prediction of amino acid changes.
Cell cultures
Primary fibroblasts, obtained by standard protocols from skin biop-
sies from patients and control subjects, were cultured in high
glucose DMEM (Euroclone) supplemented with 10% FBS/FCS, 1%
L-glutamine, HEPES 20 mM, and 1% MEM non-essential amino
acids, in a 37°C incubator with 5% CO2 and 100% humidity. All
cells were tested for mycoplasma contamination. Analyses were
performed at passages 3–7.
Immunoblot analyses
Approximately 106 cells from patients and controls were trypsi-
nized, pelleted, and solubilized. SDS–polyacrylamide gel of 50 lg
protein/lane and Western blot analysis were performed using
antibodies against XRCC4 (Santa Cruz sc-8285; Abcam Ab145),
PARP-1 (Roche), LIG4 (GenTex GTX108820), and GAPDH (Milli-
pore) as loading control. Immune-visualization was carried out by
chemiluminescence-based ECL kit (GE Healthcare). 35S-radiolabeled
in vitro-translated products corresponding to full length and the
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R225* ORFs were obtained with TNT Quick Coupled Transcription/
Translation Systems (Promega).
Cell treatments
Gamma irradiation was performed at the Department of Oncological
and Surgical Sciences of the University Padova Medical Center with
a 137Cs source (dose rate 2.8 Gy/min). Cells (20,000/sample) were
seeded on 35-mm l-Dish thin-bottomed Petri dishes for high-end
microscopy (Ibidi) in random positions 48 h before irradiation and
incubated in fresh medium for different repair times. When indi-
cated, PARP-1 inhibitor (10 mM 30-aminobenzamide in DMSO,
Sigma-Aldrich) or 0.1% DMSO was added 24 h before irradiation
and maintained throughout experiments.
Immunofluorescence staining and foci counting
At 0.5, 2, 6 and 24 h after gamma irradiation, cells were rinsed with
1× PBS and fixed with 4% formaldehyde (Sigma-Aldrich) in PBS for
15 min at 37°C. Cells were then washed twice with PBS and permea-
bilized with 0.2% Triton X-100 in PBS at 37°C for 10 min. Non-
specific binding sites were masked with horse serum (10% in PBS)
for 1 h at room temperature. Samples were incubated for 2 h at room
temperature with anti-c-H2AX (Ser139) (Millipore, Clone JBW301,
1:100), anti-RAD51 (Santa Cruz Biotechnology, H-92: sc-8349, lot.
G0811, 1:100), and anti-CENP-F (BD Bioscience, 610768, Clone 11,
1:100 or Abcam, ab5, lot. GR73067-3, 1:300) primary antibodies
followed by three washings in PBS + 0.05% Tween-20. The cells
were incubated for 1 h at room temperature with Alexa Fluor 488
goat anti-mouse and Alexa Fluor 594 donkey anti-rabbit secondary
antibodies (1:250, Life Technologies), washed three times with PBS
+ 0.05% Tween-20 and once with milli-Q water. Coverslips were
mounted on samples with Vectashield medium (Vector Laboratories)
containing 0.2 lg/ml of DAPI. Samples were acquired by Z-plane
stack scanning (500 nm thickness) using a Leica TCS SP5 confocal
microscope (Leica Microsystems) equipped with 40× oil immersion
objective. c-H2AX and RAD51 foci were scored by eye by two
different researchers from 100 nuclei for each time-point in at least
three independent experiments. The nuclear fluorescence intensity of
CENP-F protein was used to discriminate the c-H2AX and RAD51 foci
in the S-G2 and G1 cells as previously described (Bee et al, 2013).
FACS analyses
Cell cycle distribution of irradiated and non-irradiated control cells
was assessed in three independent experiments by flow cytometry
analysis of DNA content following staining with 50 lg/ll of propi-
dium iodide (Sigma-Aldrich), as previously described (Bee et al,
2013). Data were collected from 25,000 cells/sample using a BD
FACSCantoTM II flow cytometer (Becton Dickinson) and analyzed by
ModFit LT software (Verity Software House).
Statistical analysis
Statistical analyses were performed using Primer of Biostatistics
software (McGraw-Hill), and figures were prepared with Corel Draw
X6 (Corel corporation). The variance, assessed by ANOVA test, was
similar between the groups that were compared.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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